resulted only in minor changes in coagulation proteins. One week of dexamethasone every 3 weeks in the intensification phase only led to a significant decline in the level of fibrinogen (Figure 2a) , which was followed a week later by a significant increase, whereas the combination of Paronal and dexamethasone, as applied in induction, resulted in a severe decline in anticoagulant proteins and in a decreased fibrinolytic potential.
Based on these data, a hypercoagulable state was diagnosed during induction treatment only, whereas during intensification with a higher dose of Paronal in a weekly schedule combined with only 1 week of dexamethasone every 3 weeks, the risk for thrombosis was minimal. We conclude that there is a crucial interaction between asparaginase and dexamethasone in maintaining the balance between bleeding and thrombosis during therapy in childhood ALL and the effects on the coagulation system depend on the specific schedule of administration of these drugs. We read with interest that Karlsson et al. 1 successfully treated autoimmune haemolytic anaemia (AIHA) with Campath in five chronic lymphatic leukaemia patients achieving durable remissions. We were less fortunate in treating a 76-year-old gentleman diagnosed with stage C chronic lymphoid leukaemia (CLL) and diffuse marrow infiltration in December 2002.
At that time, his lymphocyte count was 673 Â 10 9 /l and cell markers revealed CD19 94%, CD23 31%, CD5/19 92%, CD38/19 22% and lambda 89%. He received pulsed dexamethasone between January and June 2003 achieving a lymphocyte count of 278 Â 10 9 /l. Between July 2003 and June 2004, he received 10 courses of fludarabine (80 mg/day for 5 days) achieving a lymphocyte count of 7.6 Â 10 9 /l but with persistent heavy marrow infiltration. In late July 2003, lymphocytes started to rise again at 32 Â 10 9 /l, then at 48 Â 10 9 /l and 77 Â 10 9 /l with a drop in haemoglobin (Hb) to 8.9 g/dl. He received seven pulses of 1 g intravenous methylprednisolone until March 2005 with relative control of the lymphocyte count that remained between 95 and 115 Â 10 9 /l, but with improvement of the Hb that remained within 11-12 g/dl. As soon as steroids were stopped, lymphocytes rapidly rose to 400 Â 10 9 /l in July 2005 with a drop in Hb to 5.3 g/l. Haemolytic anaemia had ensued with a total bilirubin of 61 mmol/l, lactate dehydrogenase at 1460 IU/l and reticulocytes at 260 Â 10 9 : a direct antiglobulin test was strongly positive for IgG and C 3 , and a free warm auto-anti E was detected by enzyme-treated Apart from Karlsson's report Campath was effective in three patients with AIHA from a British series of autoimmune cytopaenias without CLL 2 and in a further patient where coincidental AIHA and CLL were suppressed for 10 months. 3, 4 In our patient, AIHA and CLL relapsed 1 month after cessation of Campath without achieving marrow clearance. Interestingly, the CD38 marker had increased its expression on lymphoid cells post-Campath treatment in keeping with data showing enhanced CD38 expression in few patients variably treated with chlorambucil, epirubicin and fludarabine. 5 Moreover, CD38 and ZAP70 expression are predictors of poorer prognosis, as they correlate with stage, diffuse marrow infiltration and raised lymphocyte counts. 6, 7 This may explain the lack of marrow clearance that occurs in o50% of CLL patients 8 and the previous lack of response to fludarabine, which was a poor prognostic indicator in itself. Likewise deletion 11q is associated with early progressive disease, shorter progression-free survival and overall survival even in patients treated with combined chemo-and immunotherapy. 9 Sadly our patient passed away for acute renal failure secondary to untreatable haemolytic anaemia after the second course of fludarabine and cyclophosphamide before we could re-consider immunotherapy. Behaviour of lymphocyte counts and autoimmune haemolytic anaemia before, during and after Campath treatment. Lymphocyte numbers should be read on the right y axis.
